- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Efficacy and Safety of Up to 8 Years of Long-term Growth Hormone Treatment in Short Children Born Small for Gestational Age in Japan: Analysis of the Subpopulation According to the Japanese Guideline
-
- Tanaka Toshiaki
- Tanaka Growth Clinic, Tokyo, Japan
-
- Yokoya Susumu
- Department of Medical Subspecialties, National Center for Child Health and Development, Tokyo, Japan
-
- Fujieda Kenji
- Department of Pediatrics, Asahikawa Medical University, Hokkaido, Japan
-
- Seino Yoshiki
- Osaka Koseinenkin Hospital, Osaka, Japan
-
- Tada Hiroshi
- Toho University School of Medicine, Tokyo, Japan
-
- Mishina Jun
- Sanchikai Medical Corporation, Kanagawa, Japan
-
- Saito Susumu
- Pfizer Japan Inc., Tokyo, Japan
-
- Takata Ami
- Pfizer Japan Inc., Tokyo, Japan
-
- Ohki Nobuhiko
- Pfizer Japan Inc., Tokyo, Japan
Search this article
Description
The efficacy and safety of 8 yr of GH treatment was assessed in 44 Japanese children with small for gestational age (SGA) short stature who met the criteria for GH treatment initiation (height SD score (SDS) <–2.5 SD) of the Japanese guidelines. Height SDS in subjects improved throughout the study period, and average height SDS improved from –3.5 to –1.6 and from –3.4 to –1.9 in the 0.033/0.067 mg and 0.067/0.067 mg groups, respectively, after 8 yr of GH treatment. Delta height SD was approximately +2 after 4 yr of treatment, and Δ IGF-1 showed a significant positive correlation with Δ height SD after both 1 and 2 yr (r = 0.415 and 0.488, respectively) of treatment. There was no correlation between the age at the start of treatment and age at onset of puberty, and the median age at the onset of puberty in the subjects was almost the same as that in healthy children. In conclusion, clinically significant improvements in the height SDS was confirmed in short children born SGA after 8 yr of GH treatment without any safety problems.<br>
Journal
-
- Clinical Pediatric Endocrinology
-
Clinical Pediatric Endocrinology 21 (4), 57-68, 2012
The Japanese Society for Pediatric Endocrinology
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390282679459493888
-
- NII Article ID
- 10031199643
-
- NII Book ID
- AA11006467
-
- ISSN
- 13477358
- 09185739
-
- PubMed
- 23926412
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- Crossref
- CiNii Articles
- OpenAIRE
-
- Abstract License Flag
- Disallowed